Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain

European Journal of Pain (United Kingdom)

Volumn 17, Issue 3, 2013, Pages 382-393

  Yuen, E ^a   Gueorguieva, I ^a   Bueno Burgos, L ^a,c   Iyengar, S ^a   Aarons, L ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c University of Manchester ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALGESICS; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PAIN MEASUREMENT; PATIENT DROPOUTS; SEX FACTORS; SOCIOECONOMIC FACTORS; THIOPHENES; YOUNG ADULT;

EID: 84879404331     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2012.00209.x     Document Type: Article

References (21)

1. Beal, S., Sheiner, L.B., Boeckmann, A. (eds.). NONMEM User's Guides. (1989-2006) (Ellicott City, Maryland, USA, Icon Development Solutions).
2. Bird, S.B., Dickson, E.W. (2001). Clinically significant changes in pain along the visual analog scale. Ann Emerg Med 38, 639-643.
3. Bruno, R., Vivier, N., Vergnjol, J., De Phillips, S., Montay, G., Sheiner, L.B. (1996). A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation. J Pharmacokinet Biopharm. 24, 153-172.
4. Cepada, M.S., Africano, J.M., Polo, R., Alcala, R., Carr, D.B. (2003). What decline in pain intensity is meaningful to patients with acute pain? Pain 105, 151-157.
5. European Medicines Agency (EMA). (2007). Guideline on clinical medicinal products intended for the treatment of neuropathic pain. http://www.ema.europa. eu/ema.
6. Farrar, J.T., Young, J.P., Jr LaMoreaux, L., Werth, J.L., Poole, R.M. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149-158.
7. Goldstein, D., Lu, Y., Detke, M., Lee, T.C., Iyengar, S. (2005). Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116, 109-118.
8. Hanley, M.A., Jensen, M.P., Ehde, D.M., Robinson, L.R., Cardenas, D.D., Turner, J.A., Smith, D.G. (2006). Clinically significant change in pain intensity ratings in persons with spinal cord injury or amputation. Clin J Pain 22, 25-31.
9. Kjellsson, M., Zingmark, P.H., Jonsson, E.N., Karlsson, M. (2008). Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn 45, 483-501.
10. Lee, H., Kimko, H.C., Rogge, M., Wang, D., Nesterov, I.A., Peck, C.C. (2003). Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73, 348-365.
11. Lobo, E., Quinlan, T., O'Brien, L., Knadler, M., Heathman, M. (2009). Population pharmacokinetics of orally administered duloxetine in patients. Clin Pharmacokinet 48(3), 189-197.
12. Lockwood, P.A., Cook, J.A., Ewy, W.E., Mandema, J.W. (2003). The use of clinical trial simulation to support dose selection: Application to development of a new treatment for chronic neuropathic pain. Pharm Res 11, 1752-1759.
13. Moore, A., McQuay, H., Gavaghan, D. (1996). Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain 66, 229-237.
14. Nesterov, I.A., Graham, G., Duffull, S., Aarons, L., Fuseau, E., Coates, P. (2001). Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan. Pharm Res 18, 1210-1219.
15. Raskin, J., Pritchett, Y.L., Wang, F., D'Souza, D.N., Waniger, A.L., Iyengar, S., Wernicke, J.F. (2005). A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6, 346-356.
16. Rowbotham, M.C. (2001). What is a 'clinically meaningful' reduction in pain? Pain 94, 131-132.
17. Salaffi, F., Stancati, A., Silvestri, C.A., Ciapetti, A., Grassi, W. (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 8, 283-291.
18. Wernicke, J.F., Pritchett, Y.L., D'Souza, D.N., Waniger, A.L., Tran, P., Iyengar, S., Raskin, J. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67, 1411-1413.
19. Wymer, J.P., Simpson, J., Sen, D., Bongardt, S., Lacosamide SP742 Study Group. (2009). Efficacy and safety of lacosamide in diabetic neuropathic pain: An 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 25, 376-385.
20. Yano, I., Beal, S.L., Sheiner, L.B. (2001). The need for mixedeffects modeling with population dichotomous data. J Pharmacokinet Pharmacodyn 28, 389-412.
21. Zeger, S.L., Liang, K.Y., Self, S.G. (1985). The analysis of binary longitudinal data with time-independent covariates. Biometrika 72, 31-38.